Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemias: Efficacy and safety results from the AUGMENT-101 phase 1/2 study Meeting Abstract
| Authors: | Aldoss, I.; Issa, G. C.; Thirman, M. J.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G.; Perl, A.; Dickens, D.; McMahon, C. M.; Traer, E.; Zwaan, C. M.; Grove, C.; Stone, R.; Shami, P. J.; Mantzaris, I.; Greenwood, M.; Shukla, N.; Cuglievan, B.; Gu, Y.; Bagley, R. G.; Madigan, K.; Sunkaraneni, S.; Van Nguyen, H.; McNeer, N.; Stein, E. M. |
| Abstract Title: | Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemias: Efficacy and safety results from the AUGMENT-101 phase 1/2 study |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 2907 |
| Language: | English |
| ACCESSION: | WOS:001159740302016 |
| DOI: | 10.1182/blood-2023-189762 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work